Mark Stenhouse will join Exact Sciences (NASDAQ: [[ticker:EXAS]]) as president of Cologuard, a stool-based screening test for colorectal cancer the Madison, WI, company has developed.
Stenhouse spent nearly three decades at Lake Bluff, IL-based Abbott Laboratories (NYSE: [[ticker:ABT]]) and AbbVie (NYSE: [[ticker:ABBV]]), a pharmaceuticals-focused spinout of Abbott Laboratories launched in 2013. Most recently, Stenhouse was vice president of U.S. immunology at AbbVie, where he oversaw sales and marketing efforts for the blockbuster anti-inflammatory drug adalimumab (Humira), Exact said. His first day at Exact will be April 2.
Separately, Exact earlier this month named Paul Limburg the company’s co-chief medical officer. Limburg is a gastroenterologist at Mayo Clinic in Rochester, MN, and helps lead the hospital network’s Cancer Prevention and Control Program. He will continue to serve in both positions at Mayo, Exact said. The company developed Cologuard in conjunction with Mayo Clinic, and the two organizations are co-developing diagnostic tests for other types of cancer.
